TScan Therapeutics reported second quarter 2026 financial results, posting revenue of $1.1 million against a net loss of $30.4 million. The company dosed the first patient in its Phase 3 ALLOHA-2 trial for TSC-101 and shared positive manufacturing data from Cohort C of the Phase 1 ALLOHA study. Cash and cash equivalents stood at $100.2 million, sufficient to fund operations into the second quarter of 2027. The firm operates in the biotechnology industry, developing T cell receptor-engineered T cell therapies for cancer treatment.
